Viral persistence after liver transplantation for hepatitis B virus: A cross-sectional study

Transplantation

Volumn 85, Issue 8, 2008, Pages 1105-1111

  Freshwater, Dennis A ^a,b   Dudley, Tracey ^a   Cane, Patricia ^b,c   Mutimer, David J ^a,b  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

Adefovir; HBIg; Lamivudine

Indexed keywords

ADEFOVIR; AZATHIOPRINE; CYCLOSPORIN; DNA; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; MYCOPHENOLIC ACID; PREDNISOLONE; TACROLIMUS; VIRUS ANTIBODY;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECURRENT DISEASE;

ADENINE; ADULT; AGED; CROSS-SECTIONAL STUDIES; DNA, VIRAL; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; IMMUNOGLOBULINS; LAMIVUDINE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PHOSPHONIC ACIDS;

EID: 42549145493     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31816a342a     Document Type: Article

References (47)

1. Lucey MR, Graham DM, Martin P, et al. Recurrence of hepatitis B and delta hepatitis after orthotopic liver transplantation. Gut 1992; 33: 1390.
2. O'Grady J, Smith HM, Davies SE, et al. Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications. J Hepatol 1992; 14: 104.
3. Engler S, Sauer P, Klar E, et al. Prophylaxis of hepatitis B recurrence after liver transplantation with lamivudin and hepatitis B immunoglobulin. Transplant Proc 2002; 34:2285.
4. Perrillo RP, Mason AL. Hepatitis B and liver transplantation. Problems and promises. N Engl J Med 1993; 329: 1885.
5. Samuel D, Muller R, Alexander G, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993; 329: 1842.
6. McGory R, Ishitani MB, Oliveira WM, et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation 1996; 61: 1358.
7. Pruett TL, McGory R. Hepatitis B immune globulin: The US experience. Clin Transplant 2000; 14(suppl 2): 7.
8. Vierling JM. Management of HBV Infection in liver transplantation patients. Int J Med Sci 2005; 2: 41.
9. Shields PL, Owsianka A, Carman WF, et al. Selection of hepatitis B surface "escape" mutants during passive immune prophylaxis following liver transplantation: Potential impact of genetic changes on polymerase protein function. Gut 1999; 45: 306.
10. Ghany MG, Ayola B, Villamil FG, et al. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology 1998; 27: 213.
11. Hawkins AE, Gilson RJ, Gilbert N, et al. Hepatitis B virus surface mutations associated with infection after liver transplantation. J Hepatol 1996; 24: 8.
12. Protzer-Knolle U, Naumann U, Bartenschlager R, et al. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. Hepatology 1998; 27: 254.
13. Grellier L, Mutimer D, Ahmed M, et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996; 348: 1212.
14. Lo CM, Liu CL, Lau GK, et al. Liver transplantation for chronic hepatitis B with lamivudine-resistant YMDD mutant using add-on adefovir dipivoxil plus lamivudine. Liver Transpl 2005; 11: 807.
15. Mutimer D, Pillay D, Dragon E, et al. High pre-treatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation. J Hepatol 1999; 30: 715.
16. Mutimer D, Dusheiko G, Barrett C, et al. Lamivudine without HBIg for prevention of graft reinfection by hepatitis B: Long-term follow-up. Transplantation 2000; 70: 809.
17. Perrillo RP, Wright T, Rakela J, et al. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 2001; 33: 424.
18. Lo CM, Fung JT, Lau GK, et al. Development of antibody to hepatitis B surface antigen after liver transplantation for chronic hepatitis B. Hepatology 2003; 37: 36.
19. Zheng S, Chen Y, Liang T, et al. Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B Immunoglobulin prophylaxis. Liver Transpl 2006; 12: 253.
20. Gane EJ, Angus PW, Strasser S, et al. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology 2007; 132: 931.
21. Karasu Z, Ozacar T, Akyildiz M, et al. Low-dose hepatitis B immune globulin and higher-dose lamivudine combination to prevent hepatitis B virus recurrence after liver transplantation. Antivir Ther 2004; 9: 921.
22. Ali H, Egawa H, Uryuhara K, et al. Prevention of hepatitis B virus recurrence after living donor liver transplantation. Transplant Proc 2004; 36: 2764.
23. Wang ZX, Fu ZR, Ding GS, et al. Prevention of hepatitis B virus reinfection after orthotopic liver transplantation. Transplant Proc 2004; 36: 2315.
24. Villamil FG. Prophylaxis with anti-HBs immune globulins and nucleoside analogues after liver transplantation for HBV infection. J Hepatol 2003; 39: 466.
25. Dumortier J, Chevallier P, Scoazec JY, et al. Combined lamivudine and hepatitis B immunoglobulin for the prevention of hepatitis B recurrence after liver transplantation: Long-term results. Am J Transplant 2003; 3: 999.
26. Liu H, Liu YF. Liver transplantation for patients with viral hepatitis. Hepatobiliary Pancreat Dis Int 2003; 2: 28.
27. Rosenau J, Bahr MJ, Tillmann HL, et al. Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection. J Hepatol 2001; 34: 895.
28. Markowitz JS, Martin P, Conrad AJ, et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998; 28: 585.
29. Roche B, Samuel D. Evolving strategies to prevent HBV recurrence. Liver Transpl 2004; 10(10 suppl 2): S74.
30. Samuel D. Management of hepatitis B in liver transplantation patients. Semin Liver Dis 2004; 24(suppl 1): 55.
31. Terrault NA, Vyas G. Hepatitis B immune globulin preparations and use in liver transplantation. Clin Liver Dis 2003; 7: 537.
32. Perrillo R, Hann HW, Mutimer D, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004; 126: 81.
33. Schiff ER, Lai CL, Hadziyannis S, et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 2003; 38: 1419.
34. Schiff E, Lai CL, Hadziyannis S, et al. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: Final long-term results. Liver Transpl 2007; 13: 349.
35. Roche B, Feray C, Gigou M, et al. HBV DNA persistence 10 years after liver transplantation despite successful anti-HBS passive immunoprophylaxis. Hepatology 2003; 38: 86.
36. Marzano A, Salizzoni M, Bernardi-Venon W, et al. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol 2001; 34: 903.
37. Rodriguez-Frias F, Buti M, Jardi R, et al. Genetic alterations in the S gene of hepatitis B virus in patients with acute hepatitis B, chronic hepatitis B and hepatitis B liver cirrhosis before and after liver transplantation. Liver 1999; 19: 177.
38. Bahn A, Gerner P, Martine U, et al. Detection of different viral strains of hepatitis B virus in chronically infected children after seroconversion from HBsAg to anti-HBs indicating viral persistence. J Hepatol 1997; 27: 973.
39. Oon CJ, Lim GK, Ye Z, et al. Molecular epidemiology of hepatitis B virus vaccine variants in Singapore. Vaccine 1995; 13: 699.
40. Wakita T, Tokushige K, Moradpour D. Antigenic alteration of hepatitis B virus core protein in fulminant hepatitis. Hepatology 1994; 20: 295A.
41. McMahon G, Ehrlich PH, Moustafa ZA, et al. Genetic alterations in the gene encoding the major HBsAg: DNA and immunological analysis of recurrent HBsAg derived from monoclonal antibody-treated liver transplant patients. Hepatology 1992; 15: 757.
42. Cariani E, Ravaggi A, Tanzi E, et al. Emergence of hepatitis B virus S gene mutant in a liver transplant recipient. J Med Virol 1995; 47: 410.
43. Carman WF, Trautwein C, van Deursen FJ, et al. Hepatitis B virus envelope variation after transplantation with and without hepatitis B immune globulin prophylaxis. Hepatology 1996; 24: 489.
44. Zheng X, Weinberger KM, Gehrke R, et al. Mutant hepatitis B virus surface antigens (HBsAg) are immunogenic but may have a changed specificity. Virology 2004; 329: 454.
45. Lampertico P, Vigano M, Manenti E, et al. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology 2005; 42: 1414.
46. Rapti I, Dimou E, Mitsoula P, et al. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 2007; 45: 307.
47. Neff GW, Kemmer N, Kaiser TE, et al. Combination therapy in liver transplant recipients with hepatitis B virus without hepatitis B immune globulin. Dig Dis Sci 2007; 52:2497.